Silence Therapeutics (SLN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.68, -7.17% vs the prior close of $9.35.
- Volume 1.13M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SLN slides 7.2% to $8.68, a 3-month low. Closed at $8.68, -7.17% vs the prior close of $9.35. Day range $8.66–$9.22, opened at $9.10.
SLN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SLN slides 7.2% to $8.68, a 3-month low
- Closed at $8.68, -7.17% vs the prior close of $9.35. Day range $8.66–$9.22, opened at $9.10.
- Volume was 1.13M shares, 0.8x its 50-day average of 1.38M.
- Price is -29.5% vs its 50-day average ($12.31) and +3.8% vs its 200-day average ($8.36).
- 52-week range $4.19–$17.58; today's close sits at 34% of that range, 50.6% below the 52-week high.
Oct 15, 2026 — SLN jumps 4.1% to $9.35 on 1.9x normal volume
- Closed at $9.35, +4.12% vs the prior close of $8.98. Day range $8.81–$9.46, opened at $8.81.
- Volume was 2.57M shares, 1.9x its 50-day average of 1.34M — unusually heavy trading.
- Price is -24.4% vs its 50-day average ($12.37) and +12.0% vs its 200-day average ($8.35).
- 52-week range $4.19–$17.58; today's close sits at 39% of that range, 46.8% below the 52-week high.
Oct 14, 2026 — SLN rises 1.2% to $8.98
- Closed at $8.98, +1.24% vs the prior close of $8.87. Day range $8.85–$9.27, opened at $8.91.
- Volume was 1.23M shares, 0.9x its 50-day average of 1.33M.
- Price is -27.6% vs its 50-day average ($12.41) and +7.7% vs its 200-day average ($8.34).
- 52-week range $4.19–$17.58; today's close sits at 36% of that range, 48.9% below the 52-week high.
Oct 13, 2026 — SLN slides 8.1% to $8.87, a 3-month low
- Closed at $8.87, -8.08% vs the prior close of $9.65. Day range $8.71–$9.56, opened at $9.53.
- Volume was 1.45M shares, 1.1x its 50-day average of 1.31M.
- Price is -28.8% vs its 50-day average ($12.45) and +6.6% vs its 200-day average ($8.32).
- 52-week range $4.19–$17.58; today's close sits at 35% of that range, 49.5% below the 52-week high.
Oct 12, 2026 — SLN dips 2.1% to $9.65
- Closed at $9.65, -2.13% vs the prior close of $9.86. Day range $9.58–$10.35, opened at $9.70.
- Volume was 551.00K shares, 0.4x its 50-day average of 1.31M — lighter than usual.
- Price is -22.7% vs its 50-day average ($12.49) and +16.1% vs its 200-day average ($8.31).
- 52-week range $4.19–$17.58; today's close sits at 41% of that range, 45.1% below the 52-week high.
Oct 9, 2026 — SLN jumps 3.6% to $9.86
- Closed at $9.86, +3.57% vs the prior close of $9.52. Day range $9.45–$10.39, opened at $9.45.
- Volume was 844.30K shares, 0.6x its 50-day average of 1.31M.
- Price is -21.2% vs its 50-day average ($12.51) and +18.9% vs its 200-day average ($8.29).
- 52-week range $4.19–$17.58; today's close sits at 42% of that range, 43.9% below the 52-week high.
Oct 8, 2026 — SLN slides 3.1% to $9.52, a 1-month low, 6 down days in a row
- Closed at $9.52, -3.05% vs the prior close of $9.82. Day range $9.06–$9.72, opened at $9.71.
- Volume was 1.11M shares, 0.9x its 50-day average of 1.30M.
- Price is -24.1% vs its 50-day average ($12.54) and +15.0% vs its 200-day average ($8.27).
- 52-week range $4.19–$17.58; today's close sits at 40% of that range, 45.8% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — SLN ends flat (-0.1%) to $9.82, a 1-month low, 5 down days in a row
- Closed at $9.82, -0.10% vs the prior close of $9.83. Day range $9.60–$10.14, opened at $9.77.
- Volume was 1.32M shares, 1.0x its 50-day average of 1.30M.
- Price is -22.0% vs its 50-day average ($12.58) and +18.9% vs its 200-day average ($8.26).
- 52-week range $4.19–$17.58; today's close sits at 42% of that range, 44.1% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — SLN slides 3.1% to $9.83, a 1-month low, 4 down days in a row
- Closed at $9.83, -3.06% vs the prior close of $10.14. Day range $9.63–$10.19, opened at $10.12.
- Volume was 1.58M shares, 1.2x its 50-day average of 1.28M.
- Price is -22.1% vs its 50-day average ($12.62) and +19.3% vs its 200-day average ($8.24).
- 52-week range $4.19–$17.58; today's close sits at 42% of that range, 44.1% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — SLN slides 4.7% to $10.14, a 1-month low, 3 down days in a row
- Closed at $10.14, -4.70% vs the prior close of $10.64. Day range $10.05–$10.65, opened at $10.62.
- Volume was 976.30K shares, 0.8x its 50-day average of 1.26M.
- Price is -19.9% vs its 50-day average ($12.66) and +23.3% vs its 200-day average ($8.22).
- 52-week range $4.19–$17.58; today's close sits at 44% of that range, 42.3% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — SLN dips 0.7% to $10.64, a 1-month low
- Closed at $10.64, -0.65% vs the prior close of $10.71. Day range $10.38–$10.78, opened at $10.77.
- Volume was 973.30K shares, 0.8x its 50-day average of 1.25M.
- Price is -16.1% vs its 50-day average ($12.68) and +29.7% vs its 200-day average ($8.20).
- 52-week range $4.19–$17.58; today's close sits at 48% of that range, 39.5% below the 52-week high.
SLN latest news & SEC filings
Every SEC filing by or about SLN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form S-3MEF — S-3MEF filing
S-3MEF filing
Aug 10, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $224.00K) (-100.0% vs Jun 30, 2025)
- Net income: -$12.27M (prior year -$27.35M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.09 (prior year -$0.19) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 16, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 8, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SLN
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.74% (largest 8.1%).
- Liquidity: about 1.09M shares (≈$9.48M) trade per day on average.
- 52-week position: $8.68 vs a range of $4.19–$17.58 (34% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 12, 2026; 8-K Aug 10, 2026; 10-Q Aug 10, 2026.
- Share count: 141.74M shares outstanding (Jul 31, 2026), +0.0% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SLN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 9.10 | 9.22 | 8.66 | 8.68 | 1.13M |
| Oct 15, 2026 | 8.81 | 9.46 | 8.81 | 9.35 | 2.57M |
| Oct 14, 2026 | 8.91 | 9.27 | 8.85 | 8.98 | 1.23M |
| Oct 13, 2026 | 9.53 | 9.56 | 8.71 | 8.87 | 1.45M |
| Oct 12, 2026 | 9.70 | 10.35 | 9.58 | 9.65 | 551.00K |
| Oct 9, 2026 | 9.45 | 10.39 | 9.45 | 9.86 | 844.30K |
| Oct 8, 2026 | 9.71 | 9.72 | 9.06 | 9.52 | 1.11M |
| Oct 7, 2026 | 9.77 | 10.14 | 9.60 | 9.82 | 1.32M |
| Oct 6, 2026 | 10.12 | 10.19 | 9.63 | 9.83 | 1.58M |
| Oct 5, 2026 | 10.62 | 10.65 | 10.05 | 10.14 | 976.30K |
| Oct 2, 2026 | 10.77 | 10.78 | 10.38 | 10.64 | 973.30K |
| Oct 1, 2026 | 10.98 | 11.05 | 10.49 | 10.71 | 1.58M |
| Sep 30, 2026 | 10.85 | 11.30 | 10.65 | 10.93 | 1.36M |
| Sep 29, 2026 | 11.19 | 11.26 | 10.76 | 10.80 | 884.40K |
| Sep 28, 2026 | 11.13 | 11.41 | 11.01 | 11.20 | 710.70K |
| Sep 25, 2026 | 11.25 | 11.47 | 11.02 | 11.18 | 953.20K |
| Sep 24, 2026 | 11.50 | 11.70 | 11.18 | 11.22 | 691.40K |
| Sep 23, 2026 | 12.21 | 12.35 | 11.06 | 11.51 | 877.00K |
| Sep 22, 2026 | 12.27 | 12.50 | 12.17 | 12.29 | 382.10K |
| Sep 21, 2026 | 12.39 | 12.44 | 12.03 | 12.25 | 665.70K |
About Silence Therapeutics
Silence Therapeutics (SLN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LONDON. State of incorporation: United Kingdom. Fiscal year ends —. SEC CIK 1479615.
SLN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James Ede-Golightly | Director | Jan 6, 2026 |
| Rhonda Lynette Hellums | Chief Financial Officer | Jan 6, 2026 |
| David Lemus | Director | Jan 6, 2026 |
| Timothy Mcinerney | Director | Jan 6, 2026 |
| Iain Ross | Interim PEO | Dec 22, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Rhonda Lynette Hellums | Chief Financial Officer | Jan 6, 2026 |
| Steven J. Romano | EVP and Chief R&D Officer | Jan 6, 2026 |
| Iain Ross | Interim PEO | Dec 22, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
SLN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $559.00K | $-88.61M | -0.63 | $-62.27M |
| Dec 31, 2024 | $43.26M | $-45.31M | -0.33 | $-67.64M |
| Dec 31, 2023 | $31.64M | $-54.23M | -0.49 | $-49.46M |
| Dec 31, 2022 | $21.66M | $-50.33M | -0.52 | $-57.04M |
Latest balance sheet: total assets $106.41M, total liabilities $67.94M, cash $72.05M (as of Jun 30, 2026).
SLN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $15.43 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.95 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $5.50 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $6.45 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $5.38 |
| May 8, 2025 | 8-K Item 2.02 (results) | $3.56 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $4.72 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SLN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.